Class Action Lawsuits Filed Against Petco, Capricor, RxSight for Securities Fraud

Several class action securities lawsuits have been filed against companies including Petco Health and Wellness Company, Capricor Therapeutics, and RxSight, alleging violations of federal securities laws due to false or misleading statements impacting investor decisions. Petco investors are accused of being misled about the sustainability of pandemic-related tailwinds and the strength of its premium pet food business model, with a deadline of August 29, 2025, to seek lead plaintiff status. Capricor's lawsuit concerns misleading statements about its lead cell therapy drug deramiocel and the subsequent FDA rejection of its Biologics License Application, causing a sharp stock price decline. RxSight investors allege that the company concealed adoption challenges and overstated product demand, leading to missed financial guidance. Law firms Faruqi & Faruqi and Levi & Korsinsky are actively encouraging affected investors to contact them to discuss legal rights and potential recoveries, emphasizing that participation in these cases involves no out-of-pocket costs. These cases highlight ongoing scrutiny of companies' public disclosures and investor protections under securities laws.